The most commonly measured biomarkers to assess cognitive impairment are beta-amyloid protein, tau protein, light neurofilaments, and quantitative or topographic biomarkers of neurodegeneration or neuronal damage (CSF t-tau, FDG-PET, or structural MRI) [33,34]. This evidence concerns the gene MAPT and Cognitive impairment.